OCS
Oculis Holding AG
Set alert
- YTD
- -58.64%
- 1 year
- -58.89%
- Open
- 8.19
- Prev close
- 8.24
- Mkt cap
- 508.72M
- Vol
- 309.70K
- Avg vol
- 257.45K
- EPS
- -1.74
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.19
- High
- 8.84
- Forward P/E
- -6.94
- Beta
- 0.20
- Short ratio
- 1.06
- Inst. own
- 37.91%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 27.67
- 200-d avg
- 23.22
- 1y target
- 51.82
Key statistics
- Market cap
- 876.23M
- Enterprise value
- 1.11B
- Trailing P/E
- 0.00
- Forward P/E
- -6.94
- PEG ratio
- 0.00
- Price / sales
- 730.80
- Price / book
- 3.36
- EPS (TTM)
- -2.15
- Beta
- 0.20
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.20M
- Revenue growth
- 13600.00%
- Free cash flow
- -43.68M
- Total cash
- 213.01M
- Total debt
- 2.31M
- Return on equity
- -73.45%
- Shares outstanding
- 60.39M
- Short % of float
- 0.96%
- 50-day average
- 27.67
- 200-day average
- 23.22
Analyst view
Consensus: strong buy
- Target (low)
- 42.02
- Target (mean)
- 51.82
- Target (high)
- 75.07
- Strong buy3
- Buy8
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.40287.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 1, 2026 | Stifel | main | Buy | Buy |
| Jun 1, 2026 | Guggenheim | main | Buy | Buy |
| Jun 1, 2026 | Needham | main | Buy | Buy |
| Jun 1, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| May 21, 2026 | Guggenheim | init | — | Buy |
| May 18, 2026 | JP Morgan | main | Overweight | Overweight |
About Oculis Holding AG
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Switzerland
- Website
- oculis.com
News
- Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit
- Oculis to Feature Privosegtor's Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit
- HC Wainwright & Co. Reiterates Buy on Oculis Holding, Maintains $39 Price Target
- Oculis Says Phase 2 ACUITY Biomarker Data Show Privosegtor Lowered NfL, GFAP Versus Placebo In Optic Neuritis, Strengthening Confidence In PIONEER Registrational Program, Exploring Acute MS Relapses
- Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor's Neuroprotective Potential in Optic Neuritis
- Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor's Neuroprotective Potential in Optic Neuritis
- Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting
- Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting
- Oculis To Report Topline Results Around Year-End 2026 From First Genotype-Guided Registrational Dry Eye Trial Of Licaminlimab, Now Fully Randomized With 176 Patients, Two-Thirds Carrying Target TNFR1 Variant
- Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease
Your note
Sign in to keep a note on OCS — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Eqt Fund Management S.a R.l. | 10.18% | 5,900,294 | 85.61M | Mar 30, 2026 |
| Gildi - Lifeyrissjodur | 4.19% | 2,430,401 | 35.27M | Mar 30, 2026 |
| Aberdeen Group plc | 3.01% | 1,746,946 | 25.35M | Mar 30, 2026 |
| Pivotal bioVenture Partners Investment Advisor, LLC | 2.90% | 1,680,283 | 24.38M | Mar 30, 2026 |
| Wellington Management Group, LLP | 2.32% | 1,345,728 | 19.53M | Mar 30, 2026 |
| Millennium Management Llc | 1.57% | 913,034 | 13.25M | Mar 30, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| abrdn Healthcare Opportunities Fund | 1.02% | 592,229 | 8.59M | Mar 30, 2026 |
| abrdn Healthcare Investors | 1.00% | 579,536 | 8.41M | Dec 30, 2025 |
| abrdn World Healthcare Fund | 0.61% | 355,412 | 5.16M | Mar 30, 2026 |
| abrdn Life Sciences Investors | 0.44% | 253,740 | 3.68M | Dec 30, 2025 |
| HARTFORD MUTUAL FUNDS INC/CT-THE HARTFORD HEALTHCARE FUND | 0.32% | 187,112 | 2.71M | Jan 30, 2026 |
| Global Macro Absolute Return Advantage Portfolio | 0.19% | 109,990 | 1.60M | Jan 30, 2026 |